-+ 0.00%
-+ 0.00%
-+ 0.00%

From the site of the 2025 Innovative Drug High Quality Development Conference held today, we learned that Hengrui Pharmaceutical's 10 products were included in the new national medical insurance drug catalogue for the first time, covering various fields such as tumors, metabolism, cardiovascular disease, immune system diseases, ophthalmology, etc., including injectable recontrestuzumab, emaxitinib sulfate tablets, fenacizumab injections, injectable phosphorapitine, metformin tablets/, famitinib malate capsules, abiraterone acetate tablets Irinotecan hydrochloride liposome injections, perfluorohexyl octane eye drops.

Zhitongcaijing·12/07/2025 03:57:00
Listen to the news
From the site of the 2025 Innovative Drug High Quality Development Conference held today, we learned that Hengrui Pharmaceutical's 10 products were included in the new national medical insurance drug catalogue for the first time, covering various fields such as tumors, metabolism, cardiovascular disease, immune system diseases, ophthalmology, etc., including injectable recontrestuzumab, emaxitinib sulfate tablets, fenacizumab injections, injectable phosphorapitine, metformin tablets/, famitinib malate capsules, abiraterone acetate tablets Irinotecan hydrochloride liposome injections, perfluorohexyl octane eye drops.